VistaGen Therapeutics' (VTGN) "Outperform" Rating Reaffirmed at William Blair

Key Points

• VistaGen Therapeutics (VTGN) had its "outperform" rating reiterated by analysts at William Blair, while the consensus rating remains "Hold" among other research firms.
• The company reported earnings of ($0.47) per share, aligning with analysts' expectations and generating revenue of $0.24 million for the quarter.
• Institutional investors own 78.39% of the company's stock, with significant increases in holdings reported by several hedge funds in recent months.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at William Blair in a research note issued to investors on Tuesday,RTT News reports.

A number of other research firms also recently weighed in on VTGN. Weiss Ratings restated a "sell (d-)" rating on shares of VistaGen Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded VistaGen Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold".

VistaGen Therapeutics Stock Performance

NASDAQ:VTGN traded down $0.18 during mid-day trading on Tuesday, reaching $4.31. The stock had a trading volume of 345,022 shares, compared to its average volume of 311,954. The firm has a 50 day moving average price of $3.48 and a two-hundred day moving average price of $2.76. The stock has a market capitalization of $132.08 million, a P/E ratio of -2.42 and a beta of 0.55. VistaGen Therapeutics has a one year low of $1.90 and a one year high of $4.52.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.47). The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.22 million. Research analysts forecast that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On VistaGen Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in VTGN. ADAR1 Capital Management LLC raised its holdings in shares of VistaGen Therapeutics by 246.4% during the first quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company's stock valued at $1,052,000 after acquiring an additional 299,304 shares in the last quarter. Jane Street Group LLC bought a new position in shares of VistaGen Therapeutics during the second quarter valued at approximately $190,000. Stempoint Capital LP raised its holdings in shares of VistaGen Therapeutics by 2.0% during the second quarter. Stempoint Capital LP now owns 2,413,254 shares of the company's stock valued at $4,827,000 after acquiring an additional 46,700 shares in the last quarter. AdvisorShares Investments LLC raised its holdings in shares of VistaGen Therapeutics by 27.7% during the second quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company's stock valued at $406,000 after acquiring an additional 44,000 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of VistaGen Therapeutics during the second quarter valued at approximately $69,000. Institutional investors own 78.39% of the company's stock.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.